Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 473

1.

Annual banned-substance review-analytical approaches in human sports drug testing.

Thevis M, Kuuranne T, Geyer H.

Drug Test Anal. 2019 Nov 13. doi: 10.1002/dta.2735. [Epub ahead of print]

PMID:
31724288
2.

Elevated urinary cobalt concentrations identified in routine doping controls can originate from vitamin B12.

Knoop A, Görgens C, Geyer H, Thevis M.

Rapid Commun Mass Spectrom. 2019 Nov 12. doi: 10.1002/rcm.8649. [Epub ahead of print] No abstract available.

PMID:
31715649
3.

Death after misuse of anabolic substances (clenbuterol, stanozolol and metandienone).

Lehmann S, Thomas A, Schiwy-Bochat KH, Geyer H, Thevis M, Glenewinkel F, Rothschild MA, Andresen-Streichert H, Juebner M.

Forensic Sci Int. 2019 Oct;303:109925. doi: 10.1016/j.forsciint.2019.109925. Epub 2019 Aug 8.

PMID:
31499423
4.

Association of Sjögren's syndrome with myotonic dystrophy type 1.

Kitsis EA, Napier F, Juthani V, Geyer HL.

BMJ Case Rep. 2019 Aug 28;12(8). pii: e229611. doi: 10.1136/bcr-2019-229611.

PMID:
31466972
5.

Glycation of macrophages induces expression of pro-inflammatory cytokines and reduces phagocytic efficiency.

Bezold V, Rosenstock P, Scheffler J, Geyer H, Horstkorte R, Bork K.

Aging (Albany NY). 2019 Jul 29;11(14):5258-5275. doi: 10.18632/aging.102123.

6.

Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.

Palmer J, Kosiorek HE, Wolschke C, Fauble VDS, Butterfield R 3rd, Geyer H, Scherber RM, Dueck AC, Gathany A, Mesa RA, Kroger N.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2267-2273. doi: 10.1016/j.bbmt.2019.07.001. Epub 2019 Jul 6.

PMID:
31288096
7.

Development of two complementary LC-HRMS methods for analyzing sotatercept in dried blood spots for doping controls.

Lange T, Walpurgis K, Thomas A, Geyer H, Thevis M.

Bioanalysis. 2019 May;11(10):923-940. doi: 10.4155/bio-2018-0313.

PMID:
31218901
8.

Relationship between symptom burden and disability leave among patients with myeloproliferative neoplasms (MPNs): findings from the Living with MPN patient survey.

Yu J, Paranagama D, Geyer HL, Parasuraman S, Mesa R.

Ann Hematol. 2019 May;98(5):1119-1125. doi: 10.1007/s00277-019-03610-4. Epub 2019 Jan 29.

9.

Item nonresponse on the Myeloproliferative Neoplasms Symptom Assessment Form (MPN-SAF): a comparison of missing data strategies.

Mazza GL, Kunze KL, Langlais BT, Kosiorek HE, DeWees TA, Geyer HL, Scherber RM, Mesa RA, Dueck AC.

Leuk Lymphoma. 2019 Jul;60(7):1789-1795. doi: 10.1080/10428194.2018.1548705. Epub 2019 Jan 17.

PMID:
30652523
10.

Annual banned-substance review: Analytical approaches in human sports drug testing.

Thevis M, Kuuranne T, Geyer H.

Drug Test Anal. 2019 Jan;11(1):8-26. doi: 10.1002/dta.2549. Epub 2019 Jan 6. Review.

PMID:
30488582
11.

A Neuro-Musculo-Skeletal Model of Human Standing Combining Muscle-Reflex Control and Virtual Model Control.

Suzuki Y, Geyer H.

Conf Proc IEEE Eng Med Biol Soc. 2018 Jul;2018:5590-5593. doi: 10.1109/EMBC.2018.8513543.

PMID:
30441603
12.

Studies on the in vivo metabolism of the SARM YK11: Identification and characterization of metabolites potentially useful for doping controls.

Piper T, Dib J, Putz M, Fusshöller G, Pop V, Lagojda A, Kuehne D, Geyer H, Schänzer W, Thevis M.

Drug Test Anal. 2018 Nov;10(11-12):1646-1656. doi: 10.1002/dta.2527. Epub 2018 Nov 18.

PMID:
30379415
13.

The Benefit of Combining Neuronal Feedback and Feed-Forward Control for Robustness in Step Down Perturbations of Simulated Human Walking Depends on the Muscle Function.

Haeufle DFB, Schmortte B, Geyer H, Müller R, Schmitt S.

Front Comput Neurosci. 2018 Oct 9;12:80. doi: 10.3389/fncom.2018.00080. eCollection 2018.

14.

Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis.

Palmer J, Scherber R, Girardo M, Geyer H, Kosiorek H, Dueck A, Jain T, Mesa R.

Biol Blood Marrow Transplant. 2019 Feb;25(2):398-402. doi: 10.1016/j.bbmt.2018.09.033. Epub 2018 Oct 4.

PMID:
30292010
15.

Combined detection of the ActRII-Fc fusion proteins Sotatercept (ActRIIA-Fc) and Luspatercept (modified ActRIIB-Fc) in serum by means of immunoaffinity purification, tryptic digestion, and LC-MS/MS.

Walpurgis K, Thomas A, Lange T, Reichel C, Geyer H, Thevis M.

Drug Test Anal. 2018 Nov;10(11-12):1714-1721. doi: 10.1002/dta.2513. Epub 2018 Oct 30.

PMID:
30285318
16.

Effects of 3 Weeks of Oral Low-Dose Cobalt on Hemoglobin Mass and Aerobic Performance.

Hoffmeister T, Schwenke D, Krug O, Wachsmuth N, Geyer H, Thevis M, Byrnes WC, Schmidt WFJ.

Front Physiol. 2018 Sep 19;9:1289. doi: 10.3389/fphys.2018.01289. eCollection 2018.

17.

Quality of life and symptom burden among myeloproliferative neoplasm patients: do symptoms impact quality of life?

Langlais BT, Geyer H, Scherber R, Mesa RA, Dueck AC.

Leuk Lymphoma. 2019 Feb;60(2):402-408. doi: 10.1080/10428194.2018.1480768. Epub 2018 Jul 22.

PMID:
30033837
18.

Objective Assessment of Spasticity With a Method Based on a Human Upper Limb Model.

Ang WS, Geyer H, Chen IM, Ang WT.

IEEE Trans Neural Syst Rehabil Eng. 2018 Jul;26(7):1414-1423. doi: 10.1109/TNSRE.2018.2821197.

PMID:
29985151
19.

Rubella Viruses Shift Cellular Bioenergetics to a More Oxidative and Glycolytic Phenotype with a Strain-Specific Requirement for Glutamine.

Bilz NC, Jahn K, Lorenz M, Lüdtke A, Hübschen JM, Geyer H, Mankertz A, Hübner D, Liebert UG, Claus C.

J Virol. 2018 Aug 16;92(17). pii: e00934-18. doi: 10.1128/JVI.00934-18. Print 2018 Sep 1.

20.

IOC Consensus Statement: Dietary Supplements and the High-Performance Athlete.

Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, Rawson ES, Walsh NP, Garthe I, Geyer H, Meeusen R, van Loon L, Shirreffs SM, Spriet LL, Stuart M, Vernec A, Currell K, Ali VM, Budgett RGM, Ljungqvist A, Mountjoy M, Pitsiladis Y, Soligard T, Erdener U, Engebretsen L.

Int J Sport Nutr Exerc Metab. 2018 Mar 1;28(2):104-125. doi: 10.1123/ijsnem.2018-0020. Epub 2018 Mar 28.

PMID:
29589768
21.

A simple bipedal model for studying control of gait termination.

Suzuki Y, Geyer H.

Bioinspir Biomim. 2018 Mar 27;13(3):036005. doi: 10.1088/1748-3190/aaae8e.

PMID:
29582777
22.

IOC consensus statement: dietary supplements and the high-performance athlete.

Maughan RJ, Burke LM, Dvorak J, Larson-Meyer DE, Peeling P, Phillips SM, Rawson ES, Walsh NP, Garthe I, Geyer H, Meeusen R, van Loon LJC, Shirreffs SM, Spriet LL, Stuart M, Vernec A, Currell K, Ali VM, Budgett RG, Ljungqvist A, Mountjoy M, Pitsiladis YP, Soligard T, Erdener U, Engebretsen L.

Br J Sports Med. 2018 Apr;52(7):439-455. doi: 10.1136/bjsports-2018-099027. Epub 2018 Mar 14.

23.

Analytical challenges in sports drug testing.

Thevis M, Krug O, Geyer H, Walpurgis K, Baume N, Thomas A.

Anal Bioanal Chem. 2018 Mar;410(9):2275-2281. doi: 10.1007/s00216-018-0934-9. Epub 2018 Feb 14.

PMID:
29445832
24.

Predictive neuromechanical simulations indicate why walking performance declines with ageing.

Song S, Geyer H.

J Physiol. 2018 Apr 1;596(7):1199-1210. doi: 10.1113/JP275166. Epub 2018 Mar 2.

25.

Annual banned-substance review: Analytical approaches in human sports drug testing.

Thevis M, Kuuranne T, Geyer H.

Drug Test Anal. 2018 Jan;10(1):9-27. doi: 10.1002/dta.2336. Epub 2017 Dec 18. Review.

PMID:
29149502
26.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs.

Scotch AH, Kosiorek H, Scherber R, Dueck AC, Slot S, Zweegman S, Boekhorst PAWT, Commandeur S, Schouten H, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA, Geyer HL.

Leuk Res. 2017 Dec;63:34-40. doi: 10.1016/j.leukres.2017.10.002. Epub 2017 Oct 14.

PMID:
29096334
27.

Amiodarone-induced pulmonary toxicity.

Colby R, Geyer H.

JAAPA. 2017 Nov;30(11):23-26. doi: 10.1097/01.JAA.0000524713.17719.c8.

PMID:
29064934
28.

Approach to MPN Symptom Assessment.

Geyer H, Mesa RA.

Curr Hematol Malig Rep. 2017 Oct;12(5):381-388. doi: 10.1007/s11899-017-0399-5. Review.

PMID:
28942516
29.

Relation of Telemetry Use and Mortality Risk, Hospital Length of Stay, and Readmission Rates in Patients With Respiratory Illness.

Dawson N, Burton MC, Hull B, Beliles G, Pritchard I, Trautman C, Ferry L, Doyon A, Colby R, Chuu A, Kung ST, Khang T, Durocher D, Buras M, Kosiorek H, Agrwal N, Sen A, Goss D, Geyer H.

Am J Cardiol. 2017 Oct 15;120(8):1416-1420. doi: 10.1016/j.amjcard.2017.07.029. Epub 2017 Jul 25.

PMID:
28823483
30.

[Equine dentistry: Survey on Swiss horse owners].

Schiesser E, Geyer H, Kummer M, Jackson M.

Schweiz Arch Tierheilkd. 2017 Aug;159(8):437-444. doi: 10.17236/sat00125. German.

31.

A case of hypercalcaemia in an immunocompetent patient with Mycobacterium avium intracellulare.

Parsons CE, Singh S, Geyer HL.

JRSM Open. 2017 Jul 6;8(7):2054270417716614. doi: 10.1177/2054270417716614. eCollection 2017 Jul.

32.

Mumps Virus SH Protein Inhibits NF-κB Activation by Interacting with Tumor Necrosis Factor Receptor 1, Interleukin-1 Receptor 1, and Toll-Like Receptor 3 Complexes.

Franz S, Rennert P, Woznik M, Grützke J, Lüdde A, Arriero Pais EM, Finsterbusch T, Geyer H, Mankertz A, Friedrich N.

J Virol. 2017 Aug 24;91(18). pii: e01037-17. doi: 10.1128/JVI.01037-17. Print 2017 Sep 15.

33.

Recurrent belly dancer dyskinesia in pregnancy.

Meyer JA, Desai KV, Geyer HL.

Neurology. 2017 May 23;88(21):2066. doi: 10.1212/WNL.0000000000003954. No abstract available.

PMID:
28533346
34.

Expanding analytical options in sports drug testing: Mass spectrometric detection of prohibited substances in exhaled breath.

Thevis M, Krug O, Geyer H, Schänzer W.

Rapid Commun Mass Spectrom. 2017 Aug 15;31(15):1290-1296. doi: 10.1002/rcm.7903.

35.

Mass spectrometric characterization of the selective androgen receptor modulator (SARM) YK-11 for doping control purposes.

Thevis M, Piper T, Dib J, Lagojda A, Kühne D, Packschies L, Geyer H, Schänzer W.

Rapid Commun Mass Spectrom. 2017 Jul 30;31(14):1175-1183. doi: 10.1002/rcm.7886.

PMID:
28440570
36.

Evaluation of a Neuromechanical Walking Control Model Using Disturbance Experiments.

Song S, Geyer H.

Front Comput Neurosci. 2017 Mar 14;11:15. doi: 10.3389/fncom.2017.00015. eCollection 2017.

37.

The atypical excretion profile of meldonium: Comparison of urinary detection windows after single- and multiple-dose application in healthy volunteers.

Görgens C, Guddat S, Bosse C, Geyer H, Pop V, Schänzer W, Thevis M.

J Pharm Biomed Anal. 2017 May 10;138:175-179. doi: 10.1016/j.jpba.2017.02.011. Epub 2017 Feb 6.

PMID:
28213178
38.

Clinical findings, treatment, and outcome in 11 dairy heifers with breakdown injury due to interosseous medius muscle rupture.

Nuss K, Boppart J, Geyer H.

Vet Surg. 2017 Feb;46(2):197-205. doi: 10.1111/vsu.12610. Erratum in: Vet Surg. 2017 Apr;46(3):343.

PMID:
28146290
39.

Evaluation of the optimal plate position for the fixation of supraglenoid tubercle fractures in warmbloods.

Frei S, Geyer H, Hoey S, Fuerst AE, Bischofberger AS.

Vet Comp Orthop Traumatol. 2017 Mar 20;30(2):99-106. doi: 10.3415/VCOT-16-08-0121. Epub 2017 Jan 17.

PMID:
28094420
40.

Annual banned-substance review: analytical approaches in human sports drug testing.

Thevis M, Kuuranne T, Geyer H, Schänzer W.

Drug Test Anal. 2017 Jan;9(1):6-29. doi: 10.1002/dta.2139. Review.

PMID:
27885819
41.

The potential role of hematocrit control on symptom burden among polycythemia vera patients: Insights from the CYTO-PV and MPN-SAF patient cohorts.

Scherber RM, Geyer HL, Dueck AC, Kosiorek HE, Finazzi G, Cavazzina R, Masciulli A, Scarano M, Vannucchi AM, Mesa RA, Barbui T.

Leuk Lymphoma. 2017 Jun;58(6):1481-1487. doi: 10.1080/10428194.2016.1246733. Epub 2016 Nov 10.

PMID:
27830999
42.

Testing for the erythropoiesis-stimulating agent Sotatercept/ACE-011 (ActRIIA-Fc) in serum by means of Western blotting and LC-HRMS.

Walpurgis K, Thomas A, Vogel M, Reichel C, Geyer H, Schänzer W, Thevis M.

Drug Test Anal. 2016 Nov;8(11-12):1152-1161. doi: 10.1002/dta.2093. Epub 2016 Oct 13. Erratum in: Drug Test Anal. 2016 Nov;8(11-12):1162.

PMID:
27649383
43.

Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination.

Helmlin HJ, Mürner A, Steiner S, Kamber M, Weber C, Geyer H, Guddat S, Schänzer W, Thevis M.

Forensic Sci Int. 2016 Oct;267:166-172. doi: 10.1016/j.forsciint.2016.08.029. Epub 2016 Aug 28.

PMID:
27611956
44.

Associations between gender, disease features and symptom burden in patients with myeloproliferative neoplasms: an analysis by the MPN QOL International Working Group.

Geyer HL, Kosiorek H, Dueck AC, Scherber R, Slot S, Zweegman S, Te Boekhorst PA, Senyak Z, Schouten HC, Sackmann F, Fuentes AK, Hernández-Maraver D, Pahl HL, Griesshammer M, Stegelmann F, Döhner K, Lehmann T, Bonatz K, Reiter A, Boyer F, Etienne G, Ianotto JC, Ranta D, Roy L, Cahn JY, Harrison CN, Radia D, Muxi P, Maldonado N, Besses C, Cervantes F, Johansson PL, Barbui T, Barosi G, Vannucchi AM, Paoli C, Passamonti F, Andreasson B, Ferrari ML, Rambaldi A, Samuelsson J, Cannon K, Birgegard G, Xiao Z, Xu Z, Zhang Y, Sun X, Xu J, Kiladjian JJ, Zhang P, Gale RP, Mesa RA.

Haematologica. 2017 Jan;102(1):85-93. doi: 10.3324/haematol.2016.149559. Epub 2016 Aug 18.

45.

Measuring Rabbit (Oryctolagus cuniculus) Tooth Growth and Eruption by Fluorescence Markers and Bur Marks.

Wyss F, Müller J, Clauss M, Kircher P, Geyer H, von Rechenberg B, Hatt JM.

J Vet Dent. 2016 Mar;33(1):39-46.

46.

Xenon elimination kinetics following brief exposure.

Schaefer MS, Piper T, Geyer H, Schneemann J, Neukirchen M, Thevis M, Kienbaum P.

Drug Test Anal. 2017 May;9(5):666-670. doi: 10.1002/dta.2001. Epub 2016 Jun 24.

PMID:
27341380
47.

Analyses of Meldonium (Mildronate) from Blood, Dried Blood Spots (DBS), and Urine Suggest Drug Incorporation into Erythrocytes.

Tretzel L, Görgens C, Geyer H, Thomas A, Dib J, Guddat S, Pop V, Schänzer W, Thevis M.

Int J Sports Med. 2016 Jun;37(6):500-2. doi: 10.1055/s-0036-1582317. Epub 2016 May 4. No abstract available.

48.

The role of sexuality symptoms in myeloproliferative neoplasm symptom burden and quality of life: An analysis by the MPN QOL International Study Group.

Geyer HL, Andreasson B, Kosiorek HE, Dueck AC, Scherber RM, Martin KA, Butler KA, Harrison CN, Radia DH, Cervantes F, Kiladjian JJ, Reiter A, Birgegard G, Passamonti F, Senyak Z, Vannucchi AM, Paoli C, Xiao Z, Samuelsson J, Mesa RA.

Cancer. 2016 Jun 15;122(12):1888-96. doi: 10.1002/cncr.30013. Epub 2016 Apr 12.

49.

Sports drug testing using complementary matrices: Advantages and limitations.

Thevis M, Geyer H, Tretzel L, Schänzer W.

J Pharm Biomed Anal. 2016 Oct 25;130:220-230. doi: 10.1016/j.jpba.2016.03.055. Epub 2016 Mar 28. Review.

PMID:
27040951
50.

Fully automated determination of nicotine and its major metabolites in whole blood by means of a DBS online-SPE LC-HR-MS/MS approach for sports drug testing.

Tretzel L, Thomas A, Piper T, Hedeland M, Geyer H, Schänzer W, Thevis M.

J Pharm Biomed Anal. 2016 May 10;123:132-40. doi: 10.1016/j.jpba.2016.02.009. Epub 2016 Feb 10.

PMID:
26896632

Supplemental Content

Support Center